参考文献/References:
[1] Friesema EC,Grueters A,Biebermann H,et al.Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation[J].Lancet,2004,364(9443):1435-1437.DOI:10.1016/S0140-6736(04)17226-7.
[2] Groeneweg S,van Geest FS,Abac A,et al.Disease characteristics of MCT8 deficiency:an international,retrospective,multicentre cohort study[J].Lancet Diabetes Endocrinol,2020,8(7):594-605.DOI:10.1016/S2213-8587(20)30153-4.
[3] Groeneweg S,van Geest FS,Peeters RP,et al.Thyroid hormone transporters[J].Endocr Rev,2020,41(2):bnz008.DOI:10.1210/endrev/bnz008.
[4] 辛庆刚,赵澎,蔡春泉,等.一个导致Allan-Herndon-Dudley综合征的SLC16A2基因新突变[J].天津医药,2020,48(2):132-136.DOI:10.11958/20193176.
[5] 邹品芳,黄彦臻,黄中燕,等.SLC16A2基因变异一例报道并文献复习[J].中华脑科疾病与康复杂志(电子版),2020,10(3):183-186.DOI:10.3877/cma.j.issn.2095-123X.2020.03.012.
[6] 陆芬,张丽,汤健,等.Allan-Herndon-Dudley综合征4例并文献复习[J].中国实用儿科杂志,2022,37(7):532-536.DOI:10.19538/j.ek2022070613.
[7] 殷文晗,马彩云,吕楠.SLC16A2基因新发变异致Allan-Herndon-Dudley综合征1例[J].中国临床案例成果数据库,2022,4(1):E02722-E02722.DOI:10.3760/cma.j.cmcr.2022.e02722.
[8] Zhang Q,Yang Q,Zhou X,et al.Characteristics of Allan-Herndon-Dudley syndrome in Chinese children:identification of two novel pathogenic variants of the SLC16A2 gene[J].Front Pediatr,2022,10:1050023.DOI:10.3389/fped.2022.1050023.
[9] Zung A,Visser TJ,Uitterlinden AG,et al.A child with a deletion in the monocarboxylate transporter 8 gene:7-year follow-up and effects of thyroid hormone treatment[J].Eur J Endocrinol,2011,165(5):823-830.DOI:10.1530/EJE-11-0358.
[10] Wémeau JL,Pigeyre M,Proust-Lemoine E,et al.Beneficial effects of propylthiouracil plus L-thyroxine treatment in a patient with a mutation in MCT8[J].J Clin Endocrinol Metab,2008,93(6):2084-2088.DOI:10.1210/jc.2007-2719.
[11] Refetoff S,Pappa T,Williams MK,et al.Prenatal treatment of thyroid hormone cell membrane transport defect caused by MCT8 gene mutation[J].Thyroid,2021,31(5):713-720.DOI:10.1089/thy.2020.0306.
[12] Di Cosmo C,Liao XH,Dumitrescu AM,et al.A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport[J].Endocrinology,2009,150(9):4450-4458.DOI:10.1210/en.2009-0209.
[13] Ferrara AM,Liao XH,Gil-Ibáñez P,et al.Placenta passage of the thyroid hormone analog DITPA to male wild-type and Mct8-deficient mice[J].Endocrinology,2014,155(10):4088-4093.DOI:10.1210/en.2014-1085.
[14] Zada D,Tovin A,Lerer-Goldshtein T,et al.Pharmacological treatment and BBB-targeted genetic therapy for MCT8-dependent hypomyelination in zebrafish[J].Dis Model Mech,2016,9(11):1339-1348.DOI:10.1242/dmm.027227.
[15] Verge CF,Konrad D,Cohen M,et al.Diiodothyropropionic acid(DITPA)in the treatment of MCT8 deficiency[J].J Clin Endocrinol Metab,2012,97(12):4515-4523.DOI:10.1210/jc.2012-2556.
[16] Kersseboom S,Horn S,Visser WE,et al.In vitro and mouse studies supporting therapeutic utility of triiodothyroacetic acid in MCT8 deficiency[J].Mol Endocrinol,2014,28(12):1961-1970.DOI:10.1210/me.2014-1135.
[17] Delbaere J,Vancamp P,Van Herck SL,et al.MCT8 deficiency in Purkinje cells disrupts embryonic chicken cerebellar development[J].J Endocrinol,2017,232(2):259-272.DOI:10.1530/JOE-16-0323.
[18] Groeneweg S,Peeters RP,Moran C,et al.Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency:an international,single-arm,open-label,phase 2 trial[J].Lancet Diabetes Endocrinol,2019,7(9):695-706.DOI:10.1016/S2213-8587(19)30155-X.
[19] van Geest FS,Groeneweg S,van den Akker ELT,et al.Long-term efficacy of T3 analogue Triac in children and adults with MCT8 deficiency:a real-life retrospective cohort study[J].J Clin Endocrinol Metab,2022,107(3):e1136-e1147.DOI:10.1210/clinem/dgab750.
[20] Groeneweg S,Peeters RP,Visser TJ,et al.Triiodothyroacetic acid in health and disease[J].J Endocrinol,2017,234(2):R99-R121.DOI:10.1530/JOE-17-0113.
[21] Groeneweg S,Peeters RP,Visser TJ,et al.Therapeutic applications of thyroid hormone analogues in resistance to thyroid hormone(RTH)syndromes[J].Mol Cell Endocrinol,2017,458:82-90.DOI:10.1016/j.mce.2017.02.029.
[22] Iwayama H,Liao XH,Braun L,et al.Adeno associated virus 9-based gene therapy delivers a functional monocarboxylate transporter 8,improving thyroid hormone availability to the brain of Mct8-deficient mice[J].Thyroid,2016,26(9):1311-1319.DOI:10.1089/thy.2016.0060.
[23] Liao XH,Avalos P,Shelest O,et al.AAV9-MCT8 delivery at juvenile stage ameliorates neurological and behavioral deficits in a mouse Model of MCT8-deficiency[J].Thyroid,2022,32(7):849-859.DOI:10.1089/thy.2022.0034.
[24] Braun D,Schweizer U.The chemical chaperone phenylbutyrate rescues MCT8 mutations associated with milder phenotypes in patients with Allan-Herndon-Dudley syndrome[J].Endocrinology,2017,158(3):678-691.DOI:10.1210/en.2016-1530.
[25] Ramos HE,Morandini M,Carré A,et al.Pregnancy in women heterozygous for MCT8 mutations:risk of maternal hypothyroxinemia and fetal care[J].Eur J Endocrinol,2011,164(2):309-314.DOI:10.1530/EJE-10-0679.